{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"19"}],"units":"Participants"}],"description":"A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed.","groups":[{"description":"Sorafenib 400 mg PO BID","id":"OG000","title":"Angiosarcoma"},{"description":"Sorafenib 400 mg PO BID","id":"OG001","title":"MPNST"},{"description":"Sorafenib 400 mg PO BID","id":"OG002","title":"Leiomyosarcoma"},{"description":"Sorafenib 400 mg PO BID","id":"OG003","title":"Undifferentiated Pleomorphic Sarcoma"},{"description":"Sorafenib 400 mg PO BID","id":"OG004","title":"Fibrosarcoma"},{"description":"Sorafenib 400 mg PO BID","id":"OG005","title":"Other Histology"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 4 weeks","title":"Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST","type":"PRIMARY","unitOfMeasure":"participants"}